论文部分内容阅读
目的:探讨奥扎格雷钠在治疗蛛网膜下腔出血(SAH)后脑血管痉挛(CVS)中的作用。方法:80例住院SAH患者随机分成两组。治疗组在常规治疗基础上加用奥扎格雷钠治疗,分别在患者发病后3、7、14d行TCD及CT检查,观察两组患者出现CVS及再出血情况。结果:两组患者在发病后3d,CVS发病率无明显差异;在发病后7、14d治疗组CVS的发病率明显低于对照组,再出血发病率两组均无明显差异。结论:奥扎格雷钠能明显降低SAH患者迟发性CVS,不增加再出血风险。
Objective: To investigate the role of ozagrel in the treatment of cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH). Methods: Eighty hospitalized patients with SAH were randomly divided into two groups. The treatment group was treated with ozagrel sodium on the basis of routine treatment. TCD and CT were performed on the 3, 7 and 14 days after the onset of the disease, respectively. CVS and rebleeding were observed in both groups. Results: There was no significant difference in the incidence of CVS between the two groups after 3 days of onset. The incidence of CVS in the treatment group was significantly lower than that of the control group at 7 and 14 days after onset, and there was no significant difference in the incidence of rebleeding between the two groups. Conclusion: Ozagrel sodium can significantly reduce the delayed CVS in SAH patients without increasing the risk of rebleeding.